INTERNATIONAL AIDS SOCIETY
INDUSTRY LIAISON FORUM
THE ROLE OF INDUSTRY IN DEVELOPMENT OF ARV BASED PREVENTION TECHNOLOGIES FOR WOMEN

Hall 10, AIDS2008, Mexico City
4 August 2008, 18.30-20.30

Draft meeting objectives
- Update on ARV based prevention research with focus on the need for women (PreP and second generation microbicides, PMTC), progress and failures in the field and prospects for future.
- Identify issues regarding clinical trial designs and endpoints for prevention research
- Partnership with industry - Key lessons learned and future opportunities
- Priorities for research that ILF can address, building on industry investment and potential sites on the field of ARV based prevention approaches
- Identify agenda based on investigator-led research that industry can support

DRAFT AGENDA

18.30-18.40 Welcome and brief Introduction to ILF By Elly Katabira, co-chair ILF and President-Elect of IAS

18.40-19.00 Update on progress in PrEP (pre-exposure prophylaxis) - Challenges and opportunities on how to engage women in PreP trials By Javier Lama, Investigaciones Medicas en Salud, Lima, Peru

19.00-19.15 What the future holds for next generation microbicides and partnerships with industry By Zeda Rosenberg, International Partnership for Microbicides (IPM)

19.15-19.30 Microbicide trials – challenges and opportunities in conducting the trials By Alex Coutinho, Executive director of the Infectious Disease Institute at Makerere University in Kampala, Uganda

19.30-19.45 New drugs and assessment in pregnant women – implications for ARV based prevention technologies for women (TBC)

19.45-20.15 Panel discussion – Opportunities for partnerships with industry and key lessons learned
Moderated by Judith Currier, Professor of Medicine, Associate Director of the UCLA Center for Clinical AIDS Research and Education (CARE)

20.15-20.30 Concluding remarks
Elly Katabira and Judith Currier

www.iasociety.org/ILF.aspx
Speaker’s bio

Dr. Javier R. Lama

Dr. Javier R. Lama is a Medical Doctor, Specialist in Infectious and Tropical Diseases, who earned a Master's Degree in Public Health (Epidemiology) and a Certificate in International Health from University of Washington. Dr. Lama has implemented several studies describing the epidemiology of sexually transmitted diseases and HIV in vulnerable populations in Peru and South America. His principal areas of interest are related to the assessment of new HIV treatment and prevention methods, including HIV preventive vaccines and pre-exposure prophylaxis, and the surveillance of HIV drug resistance in developing countries.

Dr. Lama began his work in the HIV arena in 1995 as Field Research Coordinator for studies addressing the epidemiology of STDs and HIV and their behavioral correlates among high risk populations, including men who have sex with men (MSM) and female sex workers (FSWs) in Lima, Peru. Thereafter, he joined the Ministry of Health of Peru, coordinating the Epidemiology Unit of the National STDs and AIDS Control Program. Between 1996 and 2000, Dr. Lama provided medical care for MSM, FSWs and people living with HIV/AIDS in urban and rural health centers in different cities in Peru.

From 2001 to 2003, Dr. Lama served as Clinical Coordinator for HIV Vaccine Trial Network (HVTN) studies at the Clinical Trials Unit in Lima; he has worked as Co-Investigator not only for HVTN but also for AIDS Clinical Trials Group studies. In collaboration with the Gladstone Institute of Virology and Immunology and University of California San Francisco, Dr. Lama has linked antiretroviral drug resistance surveillance to regular HIV and STI sentinel surveillance in six cities in Peru. Since 2004, he has co-chaired the design and implementation of the “Chemprophylaxis for HIV Prevention in Men” trial, designed to evaluate if co-formulated emtricitabine/tenofovir may reduce HIV acquisition in high risk MSM, in ten clinical trial sites worldwide.

Dr. Zeda F. Rosenberg

Dr. Zeda Rosenberg is the founding Chief Executive Officer of the International Partnership for Microbicides, a non-profit product development partnership established in 2002 to prevent HIV transmission by accelerating the development and availability of a safe and effective microbicide for use by women in developing countries. Since its launch, the organization has established critical infrastructure to develop and evaluate microbicides, including formulation, manufacturing and clinical trial capabilities. In addition to raising nearly US$225 million to support its product development efforts, IPM has focused on expanding access to promising products by acquiring royalty-free licenses from several major pharmaceutical companies for drugs to develop as microbicides.

Previously, Dr. Rosenberg was the Scientific Director for the HIV Prevention Trials Network (HPTN) at Family Health International from 1999 to 2002. In that role, she assured scientific and operational coordination for clinical trials in the areas of prevention of mother-to-child, sexual and intravenous drug use transmission of HIV both domestically and internationally. From 1987-1999, Dr. Rosenberg worked in several capacities at the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH). In her role as Senior Scientist at the Division of AIDS, she was responsible for HIV prevention clinical trials in adult populations. As Assistant Director for Prevention Research, she coordinated prevention activities in the areas of HIV infection and other sexually transmitted
Dr. Rosenberg received her undergraduate degree (A.B.) in biology and mathematics from Douglass College, Rutgers University; a master’s degree (S.M.) in epidemiology and a doctoral degree (Sc.D.) in microbiology from the Harvard School of Public Health.

Dr. Alex G. Coutinho

Dr. Coutinho is executive director of the Infectious Disease Institute at Makerere University in Kampala, Uganda. From 2001 to 2007, he served as executive director of The AIDS Support Organization of Uganda (TASO), the largest AIDS care and support organization in sub-Saharan Africa. Prior to joining TASO, he worked in a range of capacities for the Royal Swaziland Sugar Corporation (RSSC) with progressively greater responsibility for community services, focusing especially on HIV. He established services including holistic prevention and care, voluntary counseling and testing, management of opportunistic infections, a TB clinic, an AIDS clinic, a peer education program as well as hospital management and palliative care for terminal AIDS patients. These services were implemented using a multi-sectoral approach that involved schools, communities, churches and unions in an expanded HIV prevention and care program. He has provided counseling and care to hundreds of AIDS patients in Uganda and Swaziland. Dr. Coutinho was a member of the interim board of the Global Fund to Fight AIDS, TB, and Malaria as the fund was established, and he also served as the vice chair of the Global Fund Technical Review Panel for two years. He has also been the vice chair of the board of the Regional AIDS Training Network (RATN), a member of the strategic advisory group for the WHO HIV/AIDS global strategy and currently a member of the scientific committee of the Academic Alliance for HIV/AIDS as well as a board member of the AIDS Information Center – the largest VCT NGO in Africa. He has published a number of articles on AIDS service provision. He holds an MBChB and an MSc from Makerere University and an MPH from the University of Witwatersrand.

Dr. Judith S. Currier

Dr. Currier is Professor of Medicine, Associate Chief, Division of Infectious Diseases and Associate Director of the Center for AIDS Research and Education Center (CARE) at the University of California Los Angeles at UCLA. Dr Currier has been actively involved in clinical care of HIV-infected adults and clinical research since 1990. During this time she has held leadership positions in the NIH sponsored AIDS Clinical Trials Group and is currently the Principal Investigator of the UCLA Clinical Trials Unit. Her areas of expertise include clinical trials of antiretroviral therapy, complications of HIV infection, HIV infection in women and sex differences in treatment outcomes. She currently serves as a member of the US DHHS guidelines panels for antiretroviral therapy.